source
- Biopharma manufacturers turn to flexible, modular facilities to meet diverse therapy demandsBiopharma development is increasingly focused on specialized and personalized treatments such as cell and gene therapies, antibody-drug conjugates and monoclonal antibodies. At the same time, the m…
- Preoperative intravesical mitomycin C cuts NMIBC recurrence risk by 77% over five yearsA recent study evaluated giving two doses of intravesical mitomycin C before transurethral resection of bladder tumor (TURBT) in patients with non‑muscle‑invasive bladder cancer (NMIBC). Compared…